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Hospital, Almelo, and 3Vascular Surgery, University Medical Centre Utrecht, Utrecht, The NetherlandsObjectives. To evaluate the feasibility and efficacy of an innovative new covered stent and adjustable deployment system
(aSpiree Covered Stent, Vascular Architects Inc., San Jose, CA, USA) in combination with remote superficial femoral
artery endarterectomy (RSFAE) for the treatment of long segment femoropopliteal occlusive disease.
Design. Prospective multi-centre trial.
Materials and methods. Sixty-two limbs in 61 patients (41 men; median age 69 years, range 40–88) with severe disabling
claudication (nZ56) or critical limb ischaemia (nZ6) were treated in five European centres with aSpire stenting after
RSFAE for long segment occlusions (mean length 25 cm). Follow-up was by duplex scanning at 1-, 6-, 12- and 18-months.
Primary, primary-assisted and secondary patency rates were analysed.
Results. The median follow-up was 17 (range 2–34) months. A mean of 1.3 stents (range 1–3) were deployed with a median
stent diameter of 7 mm (range 6–9). There were one early and 24 late failures. At 18-months the cumulative primary,
primary-assisted and secondary patency rates were 60, 70 and 72%, respectively. There were no device related adverse
events, such as kinking or fracturing and no stent migrations.
Conclusions. The aSpire stent and the delivery system are both safe and feasible in combination with RSFAE. The mid term
follow-up appears favourable in view of the long segment occlusions treated. Further follow-up is required to compare the
mid- and long-term outcomes with current stents and conventional femoropopliteal bypass.Keywords: Stents; Endarterectomy; Minimal invasive surgical procedure; Femoral artery; Atherosclerosis; Peripheral
vascular disease; Intermittent claudication.Introduction
The prevalence of intermittent claudication (IC) in the
general population aged 55–74 years is about 5% and
is caused by superficial femoral artery (SFA) occlusive
disease in 50% of patients.1–3 Progression of athero-
sclerotic disease occurs in half of patients after an
average follow-up of two-and-a-halve years.4 Arterial
reconstruction is required for symptomatic pro-
gression in 9–21% of patients per year.5–8 The manage-
ment of femoropopliteal occlusive disease remains a
challenge. Treatment options include conservative
measures, endovascular intervention, endarterectomy
or surgical bypass. Percutaneous transluminaling author. Luuk Smeets, MD, Surgical Resident,
artment, Twenteborg Hospital, Zilvermeeuw 1, 7609
he Netherlands.
: smeets_luuk@hotmail.com
0287 + 08 $35.00/0 q 2004 Elsevier Ltd. All rights reserangioplasty (PTA) and (selective) stent placement is
well established in occlusive iliac disease with 5-year
patency rates of 80%.9 However, in femoropopliteal
occlusive disease the use of stent-grafts is still of
uncertain clinical benefit and autologous venous
bypass surgery still offers the best long term patency.10
Due to the invasive nature of this last technique less
invasive alternatives are desirable. The ongoing
development of stent-grafts with improved patency
rates is promising, since they combine the advantages
of minimally invasive endovascular treatment with
the creation of an anatomical endoprosthetic smooth
conduit. Currently, high initial technical success is
obtained with femoropopliteal stenting, but the radial
expansion force of unsupported graft material is too
low to resist external compression. Conversely, the
presence of a dense metal skeleton promotes luminal
thrombosis or extensive intimal hyperplasia in
response to injury of the vessel wall. Furthermore,Eur J Vasc Endovasc Surg 29, 287–294 (2005)
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J. S. Knight et al.288covering collaterals with stent grafts can put the
viability of the limb at risk, particularly if acute
occlusion occurs.
A new stent was developed to overcome all of the
aforementioned problems. It is made from nickel
titanium (nitinol), manufactured in a double spiral
configuration and covered with a thin sleeve of
expanded polytetrafluoroethylene (ePTFE). Advan-
tages of this stent are high radial force, flexibility and
crush and kink resistance. The delivery system ensures
accurate placement, whilst the open spiral design
maintains compliance, promotes laminar flow and
allows collaterals to be preserved.
The purpose of this feasibility study was to examine
the efficacy of this new stent and its delivery system
(aSpiree, Vascular Architects Inc., San Jose, CA, USA)
in combination with remote superficial femoral artery
endarterectomy (RSFAE) for the treatment of long
segment occlusive disease of the femoropopliteal
artery in a prospective European multi-centre trial.Methods
This study was a prospective non-randomised evalu-
ation of the aSpire stent and delivery system with
patients not being evaluated on an intention to treat
basis. Thus, patients were only included once the
RSFAE procedure was successful and the guidewire
positioned beyond the distal transition zone. Between
May 2001 and September 2002, 62 limbs in 61 patients
(41 men, median age 69, range 40–88 years) were
treated in five European centres: St Antonius, Nieu-
wegein, The Netherlands; Catharina, Eindhoven, The
Netherlands; Imelda, Bonheiden, Belgium; Policlinico
S. Metteo, Pavia, Italy and Southampton General
Hospital, Southampton, UK. Local ethics committee
approval for each institution and written informed
consent for each patient was obtained prior to
enrolment into the study. Indication for treatment
was long segment occlusive disease of the femoropo-
pliteal artery, giving rise to severe disabling claudica-
tion (nZ56) or critical limb ischaemia (nZ6). Patient
characteristics are detailed in Table 1. The patients
were followed up at 1-, 6-, 12- and 18-months by
arterial colour flow duplex ultrasound scanning with
further interventions performed as clinically indi-
cated. The primary endpoints were occlusion of the
treated segment (proximal to, distal from or in the
stent) or further radiological or surgical intervention.
Data was collected via electronic submission by all
participating centres on a secured study website.Eur J Vasc Endovasc Surg Vol 29, March 2005The aSpire covered stent
The aSpire covered stent (Fig. 1) combines the
components of a vascular stent and a surgical graft.
The stent is made from nitinol, manufactured in the
shape of a double spiral and fully encapsulated with a
thin layer of ePTFE, such that there is no tissue to
metal, or metal to blood contact. The crush resistant
nitinol frame provides radial strength whilst allowing
conformability to the vessel lumen. It is also flexible
enabling it to withstand the torsional stresses typically
found in the femoropopliteal segment. The aSpire
stent is deployed via a delivery catheter that consists of
two independent shafts, one within the other. These
shafts are rotated in opposite directions to coil and
uncoil the stent. The stent can be released from either
end independently and shortening of the stent does
not occur on release. After stent expansion, if place-
ment is not optimal, it can be re-coiled, repositioned
and re-expanded. Using these controls the stent can be
deployed precisely in the desired location. This,
together with the open design, allows the distal
intimal flap to be tacked down, but the collaterals or
side branches to be preserved, which should theoreti-
cally improve durability and patency. The stent-graft is
available in lengths of 25, 50, 100 and 150 mm with a
range of diameters from 6 to 12 mm.Procedure
RSFAE is a modification of the semiclosed endarter-
ectomy and has been previously described by Ho et al.11
Under general anaesthesia a vertical incision in the
groin is made to gain access and control of the
common, deep and superficial femoral arteries. After
anticoagulation with 5000 IU of intravenous heparin,
the common femoral artery is opened via a longitudi-
nal arteriotomy extending to the origin of the SFA, and
an endarterectomy is performed with a ring stripper
(Vollmar Dissector, Aesculapw, South San Francisco,
CA, USA). Under fluoroscopic guidance the ring strip
cutter (MollRing Cuttere; Vascular Architects Inc., San
Jose, CA, USA) is advanced and a remote endarter-
ectomy is performed with removal of the diseased
segment. A guide wire is then passed across this
lesion, onto which is rail roaded, the stent delivery
catheter. Deployment of the aSpire stent is performed
under further fluoroscopic guidance ensuring a 2 cm
overlap of the distal intimal flap. It is almost always
necessary to post-dilate the aSpire to model it to the
vessel lumen and ensure complete expansion. Either a
single stent is placed in the distal endarterectomized
artery, or further stents can be placed to line the entire
Table 1. Patient characteristics and symptoms
Patient characteristics
Median age in years (range) 69 (40–88)
Males:females 41:20
Previous myocardial infarction 14
History of angina pectoris 7
Prior coronary intervention 13
Diabetes mellitus 17
Haemodialysis 1
Cerebrovascular disease 17
Thromboembolic events 2
History of smoking 51
Presenting symptoms
Rutherford classification III: 56
IV: 6
Radiographic findings
Proximal SFA lesion 22
Distal SFA/proximal popliteal lesion 40
MeanGSD length of occlusion (cm) 25.1G5.4
Run-off vessels 1: 10
2: 25
3: 27
Calcification None: 4
Mild: 23
Moderate/severe: 35
Collateral Sparing Stent-grafting and RSFAE 289artery, ensuring major side branches and collaterals
remain patent and are not occluded by the stents.Outcome definitions and statistical analysis
Stenosis was diagnosed when the peak systolic flow
velocity ratio was greater than two-and-a-half. The
absence of colour flow indicated an occlusion and was
followed by angiography. Primary patency was defined
as uninterrupted patency of the treated femoropopliteal
segment with no additional reintervention performed. If
surgical or radiological intervention was necessary for
restenosis, the artery was designated assisted primary
patent. When a successful reintervention was under-
taken following a re-occlusion of the treated artery, the
artery was classified as secondary patent. Patient
survival was calculated by Life-table analysis and
cumulative primary, primary assisted and secondary
patency rates were calculated by Kaplan–Meier plots
according to the Reporting standards of the
SVS/ISCVS.12,13 Statistical analysis was performed
with the Software Package for the Social Sciences
(version 10.0 for Windows, SPSS, Inc., Chicago, III).
Significance was determined at a P level less than .05.ResultsProcedure
All included patients underwent successful aSpirestent placement. The mean length of occlusion treated
was 25 cm (range 10–35), with a mean of 1.3 (range 1–
3) stents used per procedure. A total of, respectively, 65
and 16 stents with a length of 100 and 50 mm were
deployed with a median stent diameter of 7 mm
(range 6–9). All stents were patent on discharge with
no problems such as stent fracture or migration. The
median follow-up is 16.5 (range 2–34) months.
There were no in-hospital deaths. There was one in-
hospital myocardial event and one further patient
suffered a cardiac event at 1 month. One patient
developed an early stent failure (within 1 month),
which was thought to be due to an intimal flap and
was successfully treated with thrombolysis; the stent
later occluded at 7 months. Two further patients
developed a false aneurysm—of which one was
located around the stent—as a complication of the
remote endarterectomy: one patient required a PTFE
bypass performed at day 9; the other patient required
no further intervention. Minor wound complications
included three superficial infections, two haematomas
and two seromas, without the need for surgical
intervention.Follow-up
There were 25 failures within 18 months: 15 occlusions
(six in-stent, two proximal, one distal and six
unrecorded) and ten stenoses (five in-stentGnative
SFA, two immediately proximal, two distal and one at
both ends of the stent). The fate of these patients is
detailed in Fig. 2. There were no limb amputations.
There were in addition, two non-procedure related
deaths at 7 and 11 months.
The cumulative primary, primary-assisted and
secondary patency rates were 83.9, 95.2 and 98.4% at
6-months, 65.4, 81.6 and 83.2% at 12-months and 59.8,
69.9 and 71.5% at 18-months, respectively, (Tables 2
and 3, and Fig. 3).Discussion
Despite the high initial technical success rate of
percutaneous transluminal angioplasty (PTA) in
femoral disease, the long-term results are disappoint-
ing, particularly for long occlusions.14,15 The PTA
causes an extensive intimal dissection with conse-
quential elastic recoil and intimal hyperplasia leading
to acute re-occlusion or restenosis. Stent placement has
not resulted in improved patency.16,17 Rather, the stent
is indicated as a secondary measure to preserve the
PTA-result, should complications such as a dissectionEur J Vasc Endovasc Surg Vol 29, March 2005
Fig. 1. The aSpire covered stent and the delivery system.
J. S. Knight et al.290occur. Sub-intimal angioplasty (SIA) is feasible and
can be effective in some patients with a high
comorbidity with lower extremity arterial occlusions
and threatened limbs but has also poor patency
results.18,19 The use of an endograft—after debulking
or not—to line the treated segment completely has not
improved the patency and its indication remains
limited to aneurysmal disease, pseudoaneurysms,
arterio-venous fistulas or arterial rupture, (withFig. 2. Outcome of restenoses and occlus
Eur J Vasc Endovasc Surg Vol 29, March 20052-year primary and secondary patency rates ranging
from 14–74 to 49–83%, respectively20–23).
RSFAE is a minimal invasive endovascular pro-
cedure that enables the treatment of long segment
(O10 cm) occlusive femoropopliteal disease. It has
been extensively described by various institutions
with 5-year primary assisted patency rates similar to
prosthetic above knee bypass surgery.24–28 A stent is
placed at the remote endarterectomy endpoint toions after RSFAE and aSpire stenting.
Table 2. Kaplan–Meier estimate of primary patency rate
Event time
(months)
Number at risk
at event
Number of
events
Withdrawn Failure rate Cumulative
patency rate
Standard error
0 62 0 0 0.000 100.00 0.00
1 62 2 0 0.032 96.77 2.21
2 60 2 0 0.033 93.55 3.07
3 58 0 0 0.000 93.55 3.12
4 58 0 0 0.000 93.55 3.12
5 58 2 0 0.034 90.32 3.69
6 56 4 2 0.071 83.87 4.50
7 50 1 0 0.020 82.19 4.91
8 49 6 0 0.122 72.13 5.44
9 43 3 0 0.070 67.10 5.87
10 40 1 0 0.025 65.42 6.08
11 39 0 1 0.000 65.42 6.16
12 38 0 3 0.000 65.42 6.24
13 35 2 0 0.057 61.68 6.45
14 33 1 1 0.030 59.81 6.60
15 31 0 1 0.000 59.81 6.81
16 30 0 3 0.000 59.81 6.92
17 27 0 1 0.000 59.81 7.30
18 26 0 2 0.000 59.81 7.44
Collateral Sparing Stent-grafting and RSFAE 291create a smooth distal transition zone back to normal
intima. Previous studies have shown that the stented
area following RSFAE is unlikely to be the cause, or
site of restenosis.27,29 This does not, however, imply
that improvements in stent design are unnecessary.
The distal transition zone and the stent are located in
Hunter’s canal, an area prone to movement and
excessive forces, where high radial force and kink
resistance are required in order to prevent stent
fracture and migration. Thus, only a short stent or a
flexible longer stent can be used. Current stents suffer
from technical difficulties with non-adjustable place-
ment techniques leading to sub-optimal results and
loss of collaterals.
Endovascular femoropopliteal procedures continueTable 3. Kaplan–Meier estimate of primary-assisted patency rate
Event time
(months)
Number at risk
at event
Number of
events
Withdraw
0 62 0 0
1 62 1 0
2 61 2 0
3 59 0 0
4 59 0 0
5 59 0 0
6 59 0 2
7 57 1 1
8 55 3 0
9 52 1 0
10 51 3 0
11 48 0 1
12 47 0 3
13 44 2 0
14 42 2 2
15 38 1 2
16 35 0 4
17 31 1 0
18 30 0 2to evolve with the development of new stents and
delivery systems. The goal is to achieve long-term (i.e.
5 year) patency rates of 75%, similar to the gold
standard treatment of conventional autologous vein
bypass grafting.13,30 Stenting after RSFAE offers many
important advantages. It is a minimally invasive
procedure that may confer haemodynamic advantages
with reduced neointimal hyperplasia formation,
whilst allowing conventional surgery to be performed
if a re-occlusion with recurrence of symptoms
occurs.31 Stent-graft failure may be categorised into
early failures reflecting technical difficulties with
initial graft deployment, and late failures as a result
of disease progression.
This study reports on the use of the aSpire coveredn Failure rate Cumulative
patency rate
Standard error
0.000 100.00 0.00
0.016 98.39 1.59
0.033 95.16 2.68
0.000 95.16 2.73
0.000 95.16 2.73
0.000 95.16 2.73
0.000 95.16 2.73
0.018 93.49 3.16
0.055 88.39 4.06
0.019 86.69 4.39
0.059 81.59 4.90
0.000 81.59 5.05
0.000 81.59 5.11
0.045 77.88 5.52
0.048 74.18 5.82
0.026 72.22 6.17
0.000 72.22 6.43
0.032 69.89 6.89
0.000 69.89 7.00
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Fig. 3. Kaplan–Meier plot of the primary, primary-assisted
and secondary patency rates.
J. S. Knight et al.292stent, an innovative new stent that has been specifi-
cally developed for the femoropopliteal segment. The
unique design of the stent and delivery catheter has
several important advantages over other currently
available systems. Firstly, the vascular stent consists of
a nitinol spiral frame that is encapsulated in a thin
layer of ePTFE. The ePTFE covering provides
enhanced luminal coverage in comparison to other
nitinol stents, and yet does not occlude important
collaterals or side branches. In addition, the aSpire
covered stent exhibits longitudinal flexibility, reducing
the incidence of stent fracture and migration in an areaFig. 4. Two angiograms in different patients: the black arrows in
arrows indicate patent collaterals. On the left a patent stent wit
flexion area. On the right an occluded proximal endarterecto
collateral.
Eur J Vasc Endovasc Surg Vol 29, March 2005prone to excessive movement. The crush resistant
nitinol frame also provides radial strength whilst
allowing conformability to the vessel lumen. Finally,
the spiral design also confers haemodynamic advan-
tages over conventional endovascular stents. As a
result of the spared collaterals, flow can still be
maintained if restenosis or occlusion occurs. In four
of our patients which an occlusion occured no
secondary intervention was performed because there
was no recurrence of symptoms (Fig. 4 shows the
vessel occluded but the aSpire maintaining distal flow
through the preservation of a collateral).
Despite the technical success rate of 100%, this
study reports on the very first aSpire cases in Europe
and the follow-up results may be influenced by the
learning curve. In addition, the majority of the stent
delivery systems used were the original version,
which, being a 9 French system, were less user friendly
than the latest 7 French compatible versions. The new
system has much-improved delivery to simplify the
wrap down and expansion process.
Our 18-month primary and secondary patency rates
compare favourably with other recently published
studies. Jahnke et al. and Bray et al. describe
percutaneous Hemobahn placement over the entire
length of the femoropopliteal segment, following
angioplasty and without prior vessel debulking.32,33
Only Jahnke et al. have reported slightly better patency
results (74% at 18 months) but they included patients
with a wide range of symptoms (13% with Rutherford
categories 1 and 2) and a mean occlusion length of onlydicate the proximal and distal ends of the aSpire stent, the red
h a spared collateral showing the kink resistance in the knee-
mised segment but a patent stent as a result of a spared
Collateral Sparing Stent-grafting and RSFAE 29311 cm compared to 25 cm in this study. Occlusion
length is an important predictor of patency.34,35
Two studies have described complete endografting
of the artery with the enduring, following remote
endarterectomy in the majority of cases, with a
primary patency of 42–50% at 18 months.36,37 These
disappointing results were in part due to a high early
re-occlusion rate and restenosis at the proximal and
distal anastomosis, which contributed to its sub-
sequent withdrawal from clinical use. There is as yet
no clear evidence based advantage for disease debulk-
ing with remote endarterectomy or percutaneous
balloon dilatation. Recanalisation, however, is extre-
mely difficult in long occlusive lesions. This study
reports on patients who are most likely to benefit from
debulking: the mean occlusion length is long at 25 cm
with 56% moderate/severe vessel calcification.
Our overall cumulative primary, primary-assisted
and secondary patency rates of, respectively, 60, 70
and 72% at 18-months are comparable to the results of
Rosenthal et al. who described a primary patency of
69% and primary assisted patency of 89% at 18 months
in 40 patients treated with RSFAE and aSpire stent-
ing.38 The development of drug eluting stents, such as
the nitric oxide eluting aSpire stent, may further
improve these results and might make complete
endolining of the endarterectomised segment with
multiple aSpire stents of additional value.
In summary, the aSpire stent system allows accu-
rate, fine-tuneable stent placement with a good
technical success rate. Patency results of the aSpire
stent combined with RSFAE are still early but appear
favourable in view of the long segment occlusions
treated. Further follow-up is required to compare the
mid- and long-term outcomes with other currently
available stents.Acknowledgements
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